Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Back
Abstract Session

Periodic fever syndromes, autoinflammatory diseases, Still’s disease and MAS/HLH
General Topic: Clinical Science

12S145: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I (0757–0762)

Sunday, November 12, 2023
2:00 PM – 3:30 PM PT
Location: Room 5A-B

On Demand In Person

    Presenting Author(s)

  • EB

    Edward Behrens, MD

    CHOP
    West Chester, PA, United States

    Disclosure(s): AB2Bio: Grant/Research Support (Ongoing); Genzyme: Consultant (Terminated, July 1, 2023); Sobi: Consultant (Terminated, July 1, 2023)

  • Bruno Fautrel, MD, PhD

    Sorbonne University - APHP
    Paris, France

    Disclosure information not submitted.

  • MH

    Magdalena Harasimowicz, MD

    University of Pittsburgh Medical Center (UPMC)
    Pittsburgh, PA, United States

    Disclosure information not submitted.

  • PJ

    Pierre-Antoine Juge, MD, PhD (he/him/his)

    Division of Rheumatology, Inflammation, and Immunity Brigham & Women’s Hospital
    Boston, MA, United States

    Disclosure information not submitted.

  • STEPHANE MITROVIC, MD, MSc

    PITIE SALPETRIERE HOSPITAL, SORBONNE UNIVERSITY, APHP
    Paris, France

    Disclosure information not submitted.

  • PR

    Piero Ruscitti, MD, PhD (he/him/his)

    University of L'Aquila
    L'Aquila, L'Aquila, Italy

    Disclosure information not submitted.

Abstract oral session.

Non-CME

Presentations:

  • 2:00 PM – 2:10 PM PT
    Identification of 23 Novel COPA Rare Exonic Non-Synonymous Variants and Their Associated Autoimmune and Inflammatory Clinical Phenotypes Among 53,364 Individuals

    Presenting Author: Pierre-Antoine Juge, MD, PhD (he/him/his) – Division of Rheumatology, Inflammation, and Immunity Brigham & Women’s Hospital

  • 2:10 PM – 2:15 PM PT
    Q&A
  • 2:15 PM – 2:25 PM PT
    Clinical and Biological Characteristics of Children and Adults Affected with Still’s Disease: A Systematic Review and Meta-analysis Informing the 2023 EULAR/PReS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis and Adult-onset Still’s Disease

    Presenting Author: STEPHANE MITROVIC, MD, MSc – PITIE SALPETRIERE HOSPITAL, SORBONNE UNIVERSITY, APHP

  • 2:25 PM – 2:30 PM PT
    Q&A
  • 2:30 PM – 2:40 PM PT
    Derivation and Validation of Four Patient Clusters in Still’s Disease, Results from GIRRCS AOSD-study Group and AIDA Network Still Disease Registry

    Presenting Author: Piero Ruscitti, MD, PhD (he/him/his) – University of L'Aquila

  • 2:40 PM – 2:45 PM PT
    Q&A
  • 2:45 PM – 2:55 PM PT
    Treatment Patterns and Outcomes in Patients with Macrophage Activation Syndrome Secondary to Still’s Disease Treated with Emapalumab: The REAL-HLH Study

    Presenting Author: Edward Behrens, MD – CHOP

  • 2:55 PM – 3:00 PM PT
    Q&A
  • 3:00 PM – 3:10 PM PT
    EULAR / PreS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult Onset Still’s Disease (AOSD)

    Presenting Author: Bruno Fautrel, MD, PhD – Sorbonne University - APHP

  • 3:10 PM – 3:15 PM PT
    Q&A
  • 3:15 PM – 3:25 PM PT
    Liver Disease Is a Common Feature of HA20 That Causes Significant Morbidity Associated with Interferon Induction

    Presenting Author: Magdalena Harasimowicz, MD – University of Pittsburgh Medical Center (UPMC)

  • 3:25 PM – 3:30 PM PT
    Q&A